Trial · NCT01454102
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Nivolumab + Gemcitabine + Cisplatin | 12 | |
| Overall Study | STARTED | Arm B: Nivolumab + Pemetrexed + Cisplatin | 15 | |
| Overall Study | STARTED | Arm C10: Nivolumab + Paclitaxel + Carboplatin | 15 | |
| Overall Study | STARTED | Arm D: Nivolumab + Bevacizumab Maintenance | 12 | |
| Overall Study | STARTED | Arm E: Nivolumab + Erlotinib | 21 | |
| Overall Study | STARTED | Arm F: Nivolumab | 52 | |
| Overall Study | STARTED | Arm GH: Nivolumab + Ipilimumab | 24 | |
| Overall Study | STARTED | Arm IJ: Nivolumab + Ipilimumab | 25 | |
| Overall Study | STARTED | Arm K: Nivolumab in Squamous Histology Subjects (NSCLC) | 13 | |
| Overall Study | STARTED | Arm L: Nivolumab in Non-squamous Histology Subjects (NSCLC) | 13 | |
| Overall Study | STARTED | Arm M: Nivolumab | 12 | |
| Overall Study | STARTED | Arm N: Nivolumab + Ipilimumab | 31 | |
| Overall Study | STARTED | Arm O: Nivolumab + Ipilimumab | 40 | |
| Overall Study | STARTED | Arm P: Nivolumab + Ipilimumab | 38 | |
| Overall Study | STARTED | Arm Q: Nivolumab + Ipilimumab | 39 | |
| Overall Study | STARTED | Arm C5: Nivolumab + Paclitaxel + Carboplatin | 14 | |
| Overall Study | COMPLETED | Arm A: Nivolumab + Gemcitabine + Cisplatin | 12 | |
| Overall Study | COMPLETED | Arm B: Nivolumab + Pemetrexed + Cisplatin | 15 | |
| Overall Study | COMPLETED | Arm C10: Nivolumab + Paclitaxel + Carboplatin | 15 | |
| Overall Study | COMPLETED | Arm D: Nivolumab + Bevacizumab Maintenance | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01454102/flow